AstraZeneca Results Presentation Deck
$bn
22.9
Net debt
end 2022
$12.7bn
4.9
Cash Flow, Net Debt and 2023 Financial Guidance
Continued EBITDA improvement
CFO
Net Debt bridge
0.5
Capex
2.4
3.1
Deal payments
and receipts¹
Adjusted EBITDA².
Dividend
CEO Opening Remarks
0.1
Other
24.0
Net debt
end June 2023
$14.2bn
Financial Results
Net Debt/EBITDA: 1.9x
Net Debt/EBITDA adjusted for Alexion inventory fair value uplift: 1.7x
●
Oncology
●
BioPharmaceuticals
Rare Disease
●
Total Revenue
Excluding COVID-19 medicines: low double-digit % growth
Including COVID-19 medicines: low-to-mid single-digit %
growth
Reiterating 2023 Guidance (CER)
Core EPS
High single-digit to low double-digit %
CEO Closing Remarks
Expected FX-impact: Total Revenue: A low single-digit adverse impact
Core EPS: Low to mid single-digit adverse impact³
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
1. Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma
share purchase liability and acquisitions of subsidiaries, net of cash acquired. 2. EBITDA adding back the impact of $1,221m 12-month rolling period (FY 2022: $3,484m) unwind of inventory fair value uplift recognised on acquisition of Alexion. AstraZeneca credit
12 ratings: Moody's: short-term rating P-2, long-term rating A3, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. Assuming average June 2023 foreign exchange rates for July to December 2023. EBITDA = earnings before
interest, tax, depreciation and amortisation; CFO = net cash inflow from operating activities; EPS = earnings per share.View entire presentation